# An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

> **NCT03061643** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 42 (actual)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** Docetaxel
- **OTHER:** Androgen-Deprivation Therapy (ADT)

## Key facts

- **NCT ID:** NCT03061643
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-08
- **Primary completion:** 2022-03
- **Final completion:** 2022-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061643, "An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03061643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*